-
Funding the Fight Against Antimicrobial Resistance: Learnings From the UK and Sweden’s Pilot Incentive Programs
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Familial Hypercholesterolemia Cascade Testing in Thailand: A Comparative Analysis of Exome vs. Long-Read DNA Sequencing
Sep 9, 2025, 16:22 PM -
Epidemiological Trends in HPV-Related Cancers and Diseases in the United Kingdom
Sep 9, 2025, 16:22 PM -
Network Meta-Analysis NMA of Clinical Effectiveness of Second-Line (2L+) Treatments in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sep 9, 2025, 16:22 PM -
Are Real-World Survival Outcomes in Metastatic Breast Cancer Transportable Between the US and Austria?
Sep 9, 2025, 16:22 PM -
Pharmacoeconomic and Healthcare Aspects of the TDM-Guided Decisions on Biological Treatment of Inflammatory Diseases: Systematic Review of International Evidence
Sep 9, 2025, 16:22 PM -
Using Machine Learning to Enable Timely Postpartum Care by Reliably Detecting Deliveries
Sep 9, 2025, 16:22 PM -
What Are the Impacts of the Absence of Health Economic Evaluations for Drugs Granted an ASMR IV Rating by the French National Authority of Health (HAS)? An Analysis of Medicines Assessed Between May 2022 and May 2024
Sep 9, 2025, 16:22 PM -
The Cost of Inaction: Strengthening Nutrition in Frailty Guidelines Across Europe
Sep 9, 2025, 16:22 PM -
How Publication Bias May Overestimate the Risk of Serious Adverse Events Associated With Bisphosphonate Use
Sep 9, 2025, 16:22 PM -
Lessons Learnt From PICO Exercise Developed by the Joint Clinical Assessment Subgroup for Etranacogene Dezaparvovec
Sep 9, 2025, 16:22 PM -
Cost Utility Analysis of a Digital Peer Navigation Program for Men With Prostate Cancer
Sep 9, 2025, 16:22 PM -
Real-World Effectiveness of Systemic Therapies in Adults with KRAS(G12C) Metastatic Colorectal Cancer in Europe: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Potential Implications of EU Joint Clinical Assessment (JCA) for the UK Affiliate of a Global Pharmaceutical Company
Sep 9, 2025, 16:22 PM -
Uncertainties in Regulatory Benefit-Risk Decision Making for Innovative Anticancer Therapies: Preliminary Results From a 2011-2024 Review of Extensions of Indications
Sep 9, 2025, 16:22 PM -
Eligibility and Strategic Implications of Germany’s 2025 Confidential Pricing Reform
Sep 9, 2025, 16:22 PM -
Reference Framework, Key Decision-Making Factors, and the Impact of Critical Parameters on Listing Recommendations for Nononcologic Drugs for Rare Diseases Issued by Canadian HTA Bodies
Sep 9, 2025, 16:22 PM -
Divergent Biologic Price Archetypes: Year-on-Year List Price Evolution Pre- and Post-Biosimilar Entry in the US, Europe, and Japan
Sep 9, 2025, 16:22 PM -
The Disease Burden of Systemic Sclerosis in the Russian Federation
Sep 9, 2025, 16:22 PM -
Treatment Patterns and Healthcare Costs of Newly Diagnosed Type 1 Diabetes Patients: A Retrospective Real-World Study of Hospital Care in Tianjin, China
Sep 9, 2025, 16:22 PM
